帕金森症通过扰乱帕尔瓦胺阳性内部神经元的振荡,网络和突触活动来破坏皮质功能
Antea Minetti1, Elena Montagni1,2, Nicolò Meneghetti3,4
1Neuroscience Institute, National Research Council (CNR), 56124, Pisa, Italy.
NPJ Parkinson's disease
|July 2, 2025
概括
帕金森病通过改变运动皮层中的帕尔瓦胺阳性内部神经元 (PV-INs) 来破坏大脑节律. 这项研究揭示了皮层的不稳定性,表明可塑性作为治疗目标.
科学领域:
- 神经科学是一个神经科学.
- 神经生物学 神经生物学 神经生物学
- 帕金森病研究 帕金森病研究
背景情况:
- 帕金森病 (PD) 涉及皮质功能障碍,但涉及帕瓦胺阳性内部神经元 (PV-INs) 的机制尚不清楚.
- PV-INs调节大脑振荡和可塑性,这对运动控制至关重要.
- 了解皮层变化对于PD的新疗法目标至关重要.
研究的目的:
- 研究帕金森病对PV-IN网络和皮质振荡动态的影响.
- 在PD的小鼠模型中阐明皮层功能障碍背后的机制.
- 确定针对皮质可塑性的潜在治疗途径.
主要方法:
- 利用了帕金森病的6-氧多巴胺 (6-OHDA) 鼠标模型.
- 采用集成的电生理学记录和广场成像.
- 进行组织学分析以评估结构和细胞变化.
主要成果:
- 在PD模型中观察到运动期间的病理性皮质过活 (>100 Hz).
- 在运动皮层内记录了PV-IN连接的严重中断.
- 确定了突触失衡,微质激活和神经炎症,表明多方面的皮质反应.
结论:
- 帕金森病导致显著的皮质不稳定性和抑制功能障碍.
- 改变的PV-IN网络和振荡动态是PD相关皮质变化的关键特征.
- 皮层可塑性成为帕金森病治疗干预的有希望的目标.
相关概念视频
Parkinson's Disease: Overview
718
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
718
Parkinson's Disease: Treatment
389
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
389
Neural Regulation
40.3K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
40.3K
Excitatory and Inhibitory Effects of Neurotransmitters
10.8K
When an action potential reaches the presynaptic axon terminal, it releases neurotransmitters from the neuron into the synaptic cleft at a chemical synapse. The released neurotransmitter can be excitatory or inhibitory. The critical criteria commonly used to determine whether a molecule is a neurotransmitter at a chemical synapse are the molecule's presence in the presynaptic neuron. Second, its release is in response to strong presynaptic depolarization. And lastly, the presence of...
10.8K
Disorders of the Nervous Tissue
1.6K
Nervous tissue is a vital component of the human body's communication system, enabling us to perceive and respond to stimuli. However, like all other tissues, it is vulnerable to disorders and diseases that can significantly impact our neurological functioning.
Homeostatic Imbalances:
Alzheimer's disease manifests as a gradual decline in memory and cognitive abilities, attributed to the buildup of amyloid plaques and neurofibrillary tangles in the brain.
Parkinson's disease arises from the...
Homeostatic Imbalances:
Alzheimer's disease manifests as a gradual decline in memory and cognitive abilities, attributed to the buildup of amyloid plaques and neurofibrillary tangles in the brain.
Parkinson's disease arises from the...
1.6K
Antiepileptic Drugs: GABAergic Pathway Potentiators
671
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
671


